These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25344575)

  • 1. ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.
    Griner NB; Young D; Chaudhary P; Mohamed AA; Huang W; Chen Y; Sreenath T; Dobi A; Petrovics G; Vishwanatha JK; Sesterhenn IA; Srivastava S; Tan SH
    Mol Cancer Res; 2015 Feb; 13(2):368-79. PubMed ID: 25344575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic features of Annexin A2 expression in prostate cancer.
    Tan SH; Young D; Chen Y; Kuo HC; Srinivasan A; Dobi A; Petrovics G; Cullen J; Mcleod DG; Rosner IL; Srivastava S; Sesterhenn IA
    Pathology; 2021 Feb; 53(2):205-213. PubMed ID: 32967771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
    Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
    Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
    Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
    Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of annexin A2 in prostate cancer cells.
    Das S; Shetty P; Valapala M; Dasgupta S; Gryczynski Z; Vishwanatha JK
    Biochemistry; 2010 Mar; 49(10):2216-26. PubMed ID: 20121258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
    Bystricky B; Cierna Z; Sieberova G; Janega P; Karaba M; Minarik G; Benca J; Sedlackova T; Jurisova S; Gronesova P; Pindak D; Macuch J; Mardiak J; Mego M
    Anticancer Res; 2017 May; 37(5):2727-2734. PubMed ID: 28476852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells.
    Inokuchi J; Narula N; Yee DS; Skarecky DW; Lau A; Ornstein DK; Tyson DR
    Int J Cancer; 2009 Jan; 124(1):68-74. PubMed ID: 18924133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
    Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
    PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.
    Leshem O; Madar S; Kogan-Sakin I; Kamer I; Goldstein I; Brosh R; Cohen Y; Jacob-Hirsch J; Ehrlich M; Ben-Sasson S; Goldfinger N; Loewenthal R; Gazit E; Rotter V; Berger R
    PLoS One; 2011; 6(7):e21650. PubMed ID: 21747944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
    Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
    Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells.
    Wang T; Yuan J; Zhang J; Tian R; Ji W; Zhou Y; Yang Y; Song W; Zhang F; Niu R
    Oncotarget; 2015 Oct; 6(31):30975-92. PubMed ID: 26307676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
    Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J
    Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
    Kao CJ; Martiniez A; Shi XB; Yang J; Evans CP; Dobi A; deVere White RW; Kung HJ
    Oncogene; 2014 May; 33(19):2495-503. PubMed ID: 23728339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ERG responsive proteome in prostate cancer.
    Tan SH; Furusato B; Fang X; He F; Mohamed AA; Griner NB; Sood K; Saxena S; Katta S; Young D; Chen Y; Sreenath T; Petrovics G; Dobi A; McLeod DG; Sesterhenn IA; Saxena S; Srivastava S
    Prostate; 2014 Jan; 74(1):70-89. PubMed ID: 24115221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.